Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) just unveiled an announcement.
Clover Biopharmaceuticals has completed enrollment in an Australian Phase 2 clinical trial evaluating two respiratory combination vaccine candidates, SCB-1022 and SCB-1033, in 420 adults aged 60 to 85. The protein-based vaccines target RSV, hMPV and, in the case of SCB-1033, PIV3, and are built on the company’s prefusion-stabilized F Trimer-Tag platform.
The randomized, observer-blinded, multi-center study compares the two vaccine candidates against placebo, assessing safety, reactogenicity and immunogenicity, with initial data expected in the third quarter of 2026. Successful results could strengthen Clover’s position in the competitive respiratory vaccine field and may open new opportunities in protecting high-risk elderly populations from multiple respiratory pathogens with a single shot.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a biotechnology company focused on developing protein-based vaccines using its proprietary Trimer-Tag vaccine technology platform. The company targets major infectious diseases, positioning itself in the global vaccine market with candidates designed to address respiratory viruses that significantly impact older adults.
Average Trading Volume: 4,342,878
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.69B
For detailed information about 2197 stock, go to TipRanks’ Stock Analysis page.